Search Insights

Insights

75 Insights found for Industries > Pharmaceuticals
TITLE
Event

Inherent Obviousness: A Case Study on a Less Known but Effective Defense

9th Annual Pharma IPR Conference 2020

Location:
Mumbai, India
Event
Event

Trends in Hatch-Waxman Litigation

IPR Connexion

Location:
webinar
News Release

Schiff Hardin Named One of 10 Firms “GCs Love for Pharma Work”

BTI’s Power Ranking 2016 recognized Schiff Hardin in its top category—Clientopia®—for the firm’s work on behalf of the pharmaceutical industry.

News Release

Clients Recognize Schiff Hardin as a Top Firm in Pharma Two Years in a Row

For the second consecutive year, Schiff Hardin has been recognized as a top “Clientopia” law firm in the BTI Industry Power Rankings 2017.

News Release

IP Practice Group Leader Recognized Among World’s Leading Patent Professionals

Schiff Hardin Intellectual Property Practice Group Co-Leader Imron Aly has been recognized as a leading patent litigator in Illinois in the 2017 IAM Patent 1000 guide, based on outstanding feedback from peers and clients.

News Release

Managing Intellectual Property Recommends Schiff Hardin, Highlights Three Attorneys

Schiff Hardin has been ranked “Highly Recommended” by Managing Intellectual Property magazine in the 2017 Illinois Patent Contentious category.

News Release

Schiff Hardin Adds White Collar Defense Lawyer William Ziegelmueller in Chicago

Ziegelmueller is an experienced trial lawyer who represents individual and corporate clients in federal criminal investigations, regulatory enforcement actions, civil litigation, and corporate internal investigations.

News Release

Schiff Hardin Expands Global Generic Pharmaceuticals Practice With Addition of Kevin M. Nelson in Chicago

Schiff Hardin LLP today announced the addition of Kevin M. Nelson as a partner in its rapidly growing Intellectual Property Group.

In The News
In The News
In The News
In The News
In The News
In The News

Patel Featured on BPCIA Litigation to Watch

The Center for Biosimilars

News Release

Schiff Hardin Advises on Public Offerings in Pharma, Tech Sectors

In the last 60 days, Schiff Hardin advised on the initial public offerings (IPO) for two companies and a public offering for another company, two in pharmaceuticals and one in the tech sector.

News Release

Schiff Hardin Named “Innovation Builder” by BTI

Schiff Hardin LLP has been singled out by corporate counsel as one of only 28 percent of law firms clients view as a BTI “Innovation Builder,” which recognizes firms that bring change to the legal market through new technology, services, strategies, or structures.

News Release

Schiff Hardin Recognized Among Managing Intellectual Property IP Stars

Schiff Hardin has been ranked as ‘Recommended’ by Managing Intellectual Property magazine in the Illinois IP Stars Patent Contentious category.

News Release

Schiff Hardin Secures Patent Infringement Win

Schiff Hardin successfully secured a favorable outcome for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., which paves the way for Fresenius to market a new generic drug.

In The News
In The News
In The News
News Release

Aly Joins Center for Biosimilars Advisory Board

Intellectual Property Practice Group Co-Leader Imron Aly has joined the advisory board for the Center for Biosimilars, an online resource for emerging pharmaceutical biotechnology that discusses the current landscape for advanced health care management with top industry thought leaders.

In The News
In The News

Patel Featured on Patent Hurdles Faced by Biosimilars to Get to Market

Biosimilars Patent and Antitrust Perspectives Virtual Panel

News Release

Aly, Nelson, and Patel Named 2020 Life Sciences Stars

Intellectual Property Practice Group Co-Leaders Imron Aly and Sailesh Patel and partner Kevin Nelson were named Life Sciences Stars in the Hatch-Waxman Patent Litigation Practice Area by LMG Life Sciences in its 2020 guide.

In The News
In The News
News Release

Firm and Four Attorneys ranked in the 2020 IAM Patent 1000

Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the ninth edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.

News Release

Schiff Hardin Wins Patent Infringement Appeal

Schiff Hardin won an appeal for our client, Fresenius Kabi USA LLC, in a patent-infringement suit filed by Hospira Inc., showing a formulation patent claim is invalid and helping generics further develop the “inherent obviousness” case law.

News Release

Firm and Four Attorneys Ranked in the 2021 IAM Patent 1000

Schiff Hardin LLP is proud to announce that the firm and four of its attorneys have been ranked in the 2021 edition of IAM Patent 1000: The World’s Leading Patent Professionals, a guide that identifies top patent professionals based on 1,800 interviews with private practice and in-house professionals.

News Release

LMG Life Sciences Recognizes the Firm and 3 Partners in 2021

Schiff Hardin has been ranked “Recommended” by LMG Life Sciences in the Hatch-Waxman Patent Litigation (Generic) category of its 2021 guide.

News Release

Schiff Acted as Underwriters’ Counsel in GT Biopharma’s $23.7M Nasdaq Up-Listing Offering

Schiff Hardin LLP advised Dawson James Securities, Inc. as underwriter in GT Biopharma, Inc.’s Nasdaq up-listing offering of 4.3 million units.

News Release

Schiff Advises Altaris on its Agreement to Acquire $1.55 Billion Perrigo’s Prescription Pharmaceuticals Business

Schiff Hardin LLP represented Altaris Capital Partners, LLC, a private investment firm focused on the healthcare industry, in its agreement to acquire Perrigo Company plc’s prescription pharmaceuticals business (Rx) for $1.55 billion.

News Release

Schiff Advises Moleculin Biotech, Inc. on its $78M Public Offering

Schiff Hardin LLP advised Moleculin Biotech, Inc. in connection with its public offering of 16,414,736 shares of common stock for gross proceeds of approximately $78 million.

News Release

Schiff Counsels Altaris on its $1.55B Acquisition of Padagis

Schiff advised Altaris Capital Partners, LLC on its acquisition of Padagis LLC, formerly the generic prescription pharmaceuticals business of Perrigo Company plc, for $1.55 billion.

News Release

Schiff Counsels CNS Pharmaceuticals on $11.5M Public Offering

Schiff Hardin advised CNS Pharmaceuticals, Inc. in connection with its public offering of 5,750,000 shares of common stock and 2,875,000 warrants to purchase common stock for gross proceeds of $11.5 million.

News Release

The Legal 500 US 2021 Ranks Four Practices, 12 Attorneys

Schiff Hardin LLP is pleased to announce that four of the firm’s practice groups have been recognized in The Legal 500 United States 2021 guide, which provides a nationwide analysis of law firms that provide cutting-edge and innovative advice.

Alert

Pharma team scores rare preliminary injunction

Schiff Hardin’s pharma and life sciences patent litigation team, lead by partner Imron T. Aly, recently secured a preliminary injunction in federal court.

Alert

Pharma Giants in Antitrust Pricing Lawsuit over Biosimilars

Pfizer sued Johnson & Johnson (J&J) in federal court in Pennsylvania last week, alleging anticompetitive discounts and other actions to prevent competition with J&J’s biologic Remicade.

Alert

Supreme Court Delivers Big Patent-Dance-Limiting Win for Biosimilars

Earlier this week, the U.S. Supreme Court unanimously held, in its first case interpreting the Biologics Price Competition and Innovation Act of 2009, Sandoz Inc. v. Amgen Inc.

Blog Post

Who Won? The Verdict in the AndroGel Trial

Schiff Hardin Product Liability & Mass Torts Blog

Alert

Four Key Issues to Watch in the U.S. Biosimilars Industry

Like generic drugs in the 1980s, biosimilars today face a number of regulatory, legal, scientific, and public perception obstacles to continued growth.

Article
Article
Alert

How Pharmaceutical Companies Can Navigate FDA During Shutdown

As the government shutdown stretches on, pharmaceutical companies must manage the partial shutdown of the U.S. Food and Drug Administration (FDA).

Article

What if Pfizer Could Donate Data to NIH? One Proposal to Promote Public Good

Pfizer’s recent decision not to disclose data about Enbrel’s potential to treat Alzheimer’s disease has caused much debate about drugmakers’ obligations to the public.

Alert

Anticompetitive Patent-Listing Decision May Clear Patent Thicket for Generic Pharma Industry

The First Circuit handed the generic pharmaceutical industry an early Valentine’s Day treat earlier this month by resuscitating an antitrust suit against Sanofi by direct purchasers of insulin glargine.

Alert

Clinical Trial Impact from Coronavirus: New FDA Guidelines for Safety and Integrity

The U.S. Food and Drug Administration (FDA) issued a guidance document today outlining its procedures for conducting clinical trials of investigational products in view of the worldwide COVID-19 outbreak.

Alert

If Successful, Teva Suit Could Decrease Generic Competition

Teva Pharmaceuticals filed suit against the United States Food and Drug Administration (FDA) alleging that its glatiramer (Copaxone) falls under the revised definition of a “biological product” and should be transitioned to the system established by the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

Article